Autosomal Dominant Polycystic Kidney Disease Pipeline Insights, 2020 - ResearchAndMarkets.com

The "Autosomal Dominant Polycystic Kidney Disease - Pipeline Insight - 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Autosomal Dominant Polycystic Kidney Disease market. A detailed picture of the Autosomal Dominant Polycystic Kidney Disease pipeline landscape is provided, which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines.

The assessment part of the report embraces in-depth Autosomal Dominant Polycystic Kidney Disease commercial assessment and clinical assessment of the Autosomal Dominant Polycystic Kidney Disease pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal Dominant Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Autosomal Dominant Polycystic Kidney Disease with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Autosomal Dominant Polycystic Kidney Disease treatment.
• Autosomal Dominant Polycystic Kidney Disease key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Autosomal Dominant Polycystic Kidney Disease market.

Scope of the Report

• The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Autosomal Dominant Polycystic Kidney Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Autosomal Dominant Polycystic Kidney Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Autosomal Dominant Polycystic Kidney Disease.

Key Topics Covered

1. Report Introduction

2. Autosomal Dominant Polycystic Kidney Disease

2.1. Overview

2.2. History

2.3. Autosomal Dominant Polycystic Kidney Disease Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Autosomal Dominant Polycystic Kidney Disease Diagnosis

2.6.1. Diagnostic Guidelines

3. Autosomal Dominant Polycystic Kidney Disease Current Treatment Patterns

3.1. Autosomal Dominant Polycystic Kidney Disease Treatment Guidelines

4. Autosomal Dominant Polycystic Kidney Disease - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Autosomal Dominant Polycystic Kidney Disease companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Autosomal Dominant Polycystic Kidney Disease Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Autosomal Dominant Polycystic Kidney Disease Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Autosomal Dominant Polycystic Kidney Disease Late Stage Products (Phase-III)

7. Autosomal Dominant Polycystic Kidney Disease Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Autosomal Dominant Polycystic Kidney Disease Discontinued Products

13. Autosomal Dominant Polycystic Kidney Disease Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Autosomal Dominant Polycystic Kidney Disease Key Companies

15. Autosomal Dominant Polycystic Kidney Disease Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Autosomal Dominant Polycystic Kidney Disease Unmet Needs

18. Autosomal Dominant Polycystic Kidney Disease Future Perspectives

19. Autosomal Dominant Polycystic Kidney Disease Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Companies Mentioned

• Palladio Biosciences
• Otsuka Pharmaceutical Co. Ltd.
• Reata Pharmaceuticals, Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tpk0n5

View source version on businesswire.com: https://www.businesswire.com/news/home/20200702005281/en/